U.S. Markets close in 3 hrs 40 mins

Sumitomo Chemical Company, Limited (SMM.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
3.3400-0.1600 (-4.57%)
As of 03:59PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.5000
Bid3.0600 x 545600
Ask3.3600 x 532400
Day's Range3.2000 - 3.4000
52 Week Range3.2000 - 4.4800
Avg. Volume4
Market Cap5.529B
Beta (5Y Monthly)0.93
PE Ratio (TTM)556.67
EPS (TTM)0.0060
Earnings DateN/A
Forward Dividend & Yield0.18 (5.17%)
Ex-Dividend DateMar 30, 2023
1y Target EstN/A
  • American City Business Journals

    Peninsula drug company Myovant to go private in $1.7 billion buyout

    A company led by former Genentech Inc. president Myrtle Potter will buy part of Brisbane-based drug maker Myovant Sciences Ltd. and take the company private in a $1.7 billion deal. The buyout by New York-based Sumitovant Biopharma Ltd. and parent company Sumitomo Pharma Co. Ltd. of Japan puts the value of Myovant (NYSE: MYOV) at $2.9 billion. Myovant, which in six years built to nearly 600 employees and developed two drugs approved for three conditions in women's health and prostate cancer, earlier this month rejected a buyout offer by the group of companies controlled by Sumitomo Chemical Co. Ltd. At that time, Myovant's board said that $22.75-per-share bid for the 48% stake the group didn't already own "significantly" undervalued Myovant.

  • American City Business Journals

    'Significantly' undervalued $1 billion offer for Peninsula biopharma sends stock soaring

    The company, which has three approved products for women's health and prostate cancer, said the offer undervalues it.

  • PR Newswire

    Ginkgo Bioworks Announces Latest Collaboration for Beauty and Personal Care Industry with Sumitomo Chemical

    Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broader collaboration with Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies. Through this partnership, Sumitomo Chemical will leverage Ginkgo's extensive codebase and expertise in organism engineering to produce molecules in a sustainable fashion that are used in products across a broad range of industries. Th